Notice of Results

RNS Number : 2015Q

Tissue Regenix Group PLC

08 September 2017

 

Tissue Regenix Group plc

Notice of Interim Results and Capital Markets Day

Leeds, 8 September 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, today gives notice that it will announce its interim results for the six months ending 31 June 2017, on Thursday 28 September 2017.

The Group will also host a Capital Markets Day in London on Thursday 12 October where it will provide an update on business activities and the integration of CellRight Technologies, with presentations from top level UK and US management.

For more Information:

Tissue Regenix Group plc Caitlin Pearson, Corporate Communications Director	Tel: [phone]
Jefferies International Ltd Simon Hardy / Christopher Binks	Tel:  [phone]
FTI Consulting Brett Pollard/ Mo Noonan/ Rob Winder	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

NORZMGGLKRVGNZG